Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients

NCT04817774 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
26
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sangamo Therapeutics